VGI Health Technology Limited (
VTL's CEO and Managing Director, Dr Glenn Tong said "This financing facility allows VTL to access cash which it would only have had access to in the first quarter of the next financial year and is very helpful in the management of the Company's cash flow especially during the present time when our two Phase II clinical studies in Non-Alcoholic Fatty Liver Disease (NAFLD) and Pancreatic Cancer are about to commence."
About VGI Health Technology Limited
VGI Health Technology Limited (NSX:VTL) is an Australian public listed biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.
Contact
Glenn TongCEO and Managing Director
Ph: +61 (0) 412 193 350
Andrew Crook
Investor and Media Relations
Ph:+61 (0) 419 788 431
Catriona Glover
Company Secretary
Tel: +61 (0) 402 328 200
Related Companies
Related Industry Topics: